Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell LymphomaFrancine M. Foss, Madeleine Duvic, H. Miles Prince et al.|Journal of Clinical Oncology|2024Cited by 22